Web Content Display

For more information you can also call 1-866-257-2597. What Are the Ingredients In Tadalafil Tablets? This Patient Information has been approved by the U.S.

Food and Drug Administration *The brands listed are trademarks of their respective owners and are not trademarks of Solco Healthcare US, LLC. The makers of these brands are not affiliated with and do not endorse Solco Healthcare US, LLC or its products. PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Container Label-5 mgRx onlyNDC 68788-8465Tadalafil tablets, USPTablets should not be split.Entire dose should be taken.Usual Dosage: See accompanying literature for dosage.Each tablet contains 5 mg of tadalafil, USP.Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°C to 86°F) [see USP Controlled Room Temperature].Warning: Keep out of reach of children.Dispense in a tight container.Print Patient Information at: by:Zhejiang Huahai Pharmaceutical Co., Ltd.Xunqiao, Linhai, Zhejiang 317024, ChinaDistributed by:Solco Healthcare US, LLCSomerset, NJ 08873, USARevised.

8.6 Hepatic Impairment

Abdi İbrahim won awards in 5 categories, including the “Pharmaceutical Company with the Most R&D Investments” category. News Abdi İbrahim Foundation House of Kindness Open NowProviding accommodation for children and their families who come to Istanbul for cancer treatmentAbdi İbrahim, the leader of the Turkish pharmaceutical industry, has initiated a social project for children undergoing cancer treatment and their families. Abdi İbrahim Foundation House of Kindness, which provides accommodation for children who come to İstanbul for cancer treatment but face difficulties staying due to economic reasons, has opened its doors in Fatih, İstanbul. Speaking at the opening ceremony, Nesrin Barut Esirtgen, Deputy Chairperson of Abdi İbrahim and Chairperson of the Board of Trustees of the Abdi İbrahim Foundation, said: “Taking into account the accommodation needs of our children and their relatives who come to Istanbul for treatment, we realized the House of Kindness project to be part of the solution. We strongly believe that kindness and the passion for healing are contagious.

Typical dosages

Our House of Kindness is a reflection of this belief and will.” D.. News Abdi İbrahim and GSK Türkiye Make Major Investment for Domestic Production of Respiratory MedicineThe Sterile Inhalation Facility, jointly developed by Abdi İbrahim and GSK Türkiye in collaboration with the Investment Office of the Presidency of the Republic of Türkiye, commences operations.The facility, built with an investment of TRY 340 million, will enable Türkiye to benefit from the advanced ‘nebule’ technology, which is used in the treatment of respiratory diseases. The facility is the first in the world capable of manufacturing the complete range of GSK’s nebule portfolio. News The First "Mab" Biotech Pharmaceutical to be Locally Manufactured in Türkiye Will Bear the Mark of AbdiBio from the Cellular LevelANOTHER FIRST FROM ABDİ İBRAHİMAbdi İbrahim, the leader in the Turkish pharmaceutical industry for 21 years, continues its unwavering commitment to investing in biotechnology. Abdi İbrahim has announced a technology transfer agreement with the Spanish biosimilar developer, mAbxience, which is among the world’s leading companies in the field.Accordingly, a currently imported cancer drug will now be manufactured tadalafil 10mg daily by AbdiBio.

Patient characteristics

Nezih Barut, Chairman of Abdi İbrahim, noted the technology transfer’s significance as the first “cell-to-end product” biotech pharmaceutical in Türkiye. News Türkiye's Leading Pharmaceutical Company Expands its Portfolio and Presence in Consumer HealthABDİ İBRAHİM STRIKES DEAL WITH ARONPHARMAAbdi İbrahim, Türkiye's leading pharmaceutical company and a strong player in consumer health products, is collaborating with Aronpharma, a key European company specializing in innovative food supplements for their innovative brand Berroxin.Abdi İbrahim has acquired sales and distribution rights in Türkiye for products that help support the immune system under the Berroxin brand of Aronpharma, which offers innovative food supplement products. The portfolio will be launched in the Turkish market starting in 2023 with the assurance of Abdi İbrahim. News Abdi İbrahim Secures a Coveted Spot as the First Turkish Pharmaceutical Company on the CDP's Climate A ListThe unrivalled leader in the Turkish pharmaceutical industry for 22 years, Abdi İbrahim attains a noteworthy achievement by earning a coveted spot on the Climate A list within the 2023 Carbon Disclosure Project (CDP) Climate Change Program. For 112 years marked by a passion for progress, Abdi İbrahim has actively embraced the green transformation by diligently integrating environmental considerations into its business models. Usual Dosage: See accompanying literature for dosage. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°C to 86°F) [see USP Controlled Room Temperature]. Warning: Keep out of reach of children. Product ACETYLSALICYLIC ACID /100 mg Enteric Coated TabletPlatelet aggregation inhibitors (COX inhibitors) Product OLANZAPINE /2.5 mg & 5 mg & 10 mg & 20 mg TabletAtypical Antipsychotics - Schizophrenia Product FLUTICASONE + SALMETEROL /50 mcg/100mcg Dry Powder InhalerAdrenergics (B2 agonists) in combination with corticosteroids - Asthma erectile dysfunction pills tadalafil & COPD Product LEVOTHYROXINE SODIUM /25mcg; 50mcg; 75mcg; 100mcg; 125mcg; 150mcg; 200mcg TabletThyroid Preparations - Hypothyroidism Product LEVETIRACETAM / 500 mg & 750 mg & 1000 mg TabletAntiepileptic Product ESCITALOPRAM / 5 mg; 10 mg; 20 mg Tablet; 10 mg/ml oral dropsSelective serotonin reuptake inhibitors - Antidepressants Product ENTECAVIR / 0,5 mg; 1 mg TabletNucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B Product TENOFOVIR DISOPROXIL / 245 mg TabletNucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B Product OTILONIUM + SIMETICONE / 40 mg + 80 mg TabletAnticholinergics & anti-floating agents (combi)- Functional gastrointestinal disorders Product LEVOCETIRIZINE + MONTELUKAST / 5 mg + 10 mg TabletAntihistaminics & Leukotriene receptor antagonists (combi)- Rhinitis & Asthma News Abdi İbrahim Receives 'Equal Opportunity Model' Certificate for Women's EmploymentAbdi İbrahim has been awarded the 'Equal Opportunity Model' (FEM) certificate, developed by KAGIDER with the technical support of the World Bank, to promote gender equality in business life and enhance women's productivity.

Deniz Daver, President of Human and Culture Group, expressed their happiness in receiving this certificate, stating, “This certificate, which acknowledges companies' sensitive approaches to gender equality and women's empowerment in employment, is an important indicator reflecting Abdi İbrahim's vision of inclusiveness. We see FEM certificate as a reward for our determined and continuous efforts in this field. Brochure HEALING THE LIVES, HEALING THE FUTURE THAT’S WHAT WE DO.Turkish pharmaceutical industry leader Abdi Ibrahim s journey began in 1912.In addition to its partnerships with more than 30 licensing firms across the globe, Abdi Ibrahim develops its own products with 250 brands and 500 products.Abdi Ibrahim has subsidiaries operating in 17 countries outside Turkey, exports to more than 70 countries from the European Union to Canada, North Africa to Asia and generates the highest employment rate in the Turkish pharmaceutical industry with 5500 qualified employees. News R&D Award to Abdi İbrahim in 5 CategoriesAbdi İbrahim, the uninterrupted leader of the Turkish pharmaceutical industry for 21 years, received awards in 5 categories at the Crystal Mortar Awards organized by the Chemists' Association.Acting for 111 years with the mission of improving life, Abdi İbrahim received awards in 5 categories at the Crystal Mortar Awards, given within the scope of the 11th International Pharmaceutical Chemistry Congress for its R&D studies and investments.

Before Using

Key takeaways

On the opening day of the 11th International Pharmaceutical Chemistry Congress organized by the Chemists' Association in Antalya this year, the R&D activities of pharmaceutical companies were awarded in 7 categories. Abdi İbrahim won awards in 5 categories, including the “Pharmaceutical Company with the Most R&D Investments” category.

• Some people may experience nasal congestion or dizziness.
• Use caution when combining with other erectile dysfunction drugs.
• Always keep medication out of reach of children.

News Abdi İbrahim Foundation House of Kindness Open NowProviding accommodation for children and their families who come to Istanbul for cancer treatmentAbdi İbrahim, the leader of the Turkish pharmaceutical industry, has initiated a social project for children undergoing cancer treatment and their families. Abdi İbrahim Foundation House of Kindness, which provides accommodation for children who come to İstanbul for cancer treatment but face difficulties staying due to economic reasons, has opened its doors in Fatih, İstanbul. Speaking at the opening ceremony, Nesrin Barut Esirtgen, Deputy Chairperson of Abdi İbrahim and Chairperson of the Board of Trustees of the Abdi İbrahim Foundation, said: “Taking into account the accommodation needs of our children and their relatives who come to Istanbul for treatment, we realized the House of Kindness project to be part of the solution. We strongly believe that kindness and the passion for healing are contagious. Our House of Kindness is a reflection of this belief and will.” D..

Overdose/Missed Dose

News Abdi İbrahim and GSK Türkiye Make Major Investment for Domestic Production of Respiratory MedicineThe Sterile Inhalation Facility, jointly developed by Abdi İbrahim and GSK Türkiye in collaboration with the Investment Office of the Presidency of the Republic of Türkiye, commences operations.The facility, built with an investment of TRY 340 million, will enable Türkiye to benefit from the advanced ‘nebule’ technology, which is used in the treatment of respiratory diseases. The facility is the first in the world capable of manufacturing the complete range of GSK’s nebule portfolio.

6.1 Clinical Trials Experience

News The First "Mab" Biotech Pharmaceutical to be Locally Manufactured in Türkiye Will Bear the Mark of AbdiBio from the Cellular LevelANOTHER FIRST FROM ABDİ İBRAHİMAbdi İbrahim, the leader in the Turkish pharmaceutical industry for 21 years, continues its unwavering commitment to investing in biotechnology. Abdi İbrahim has announced a technology transfer agreement with the Spanish biosimilar developer, mAbxience, which is among the world’s leading companies in the field.Accordingly, a currently imported cancer drug will now be manufactured tadalafil 10mg daily by AbdiBio. Nezih Barut, Chairman of Abdi İbrahim, noted the technology transfer’s significance as the first “cell-to-end product” biotech pharmaceutical in Türkiye. News Türkiye's Leading Pharmaceutical Company Expands its Portfolio and Presence in Consumer HealthABDİ İBRAHİM STRIKES DEAL WITH ARONPHARMAAbdi İbrahim, Türkiye's leading pharmaceutical company and a strong player in consumer health products, is collaborating with Aronpharma, a key European company specializing in innovative food supplements for their innovative brand Berroxin.Abdi İbrahim has acquired sales and distribution rights in Türkiye for products that help support the immune system under the Berroxin brand of Aronpharma, which offers innovative food supplement products. The portfolio will be launched in the Turkish market starting in 2023 with the assurance of Abdi İbrahim. News Abdi İbrahim Secures a Coveted Spot as the First Turkish Pharmaceutical Company on the CDP's Climate A ListThe unrivalled leader in the Turkish pharmaceutical industry for 22 years, Abdi İbrahim attains a noteworthy achievement by earning a coveted spot on the Climate A list within the 2023 Carbon Disclosure Project (CDP) Climate Change Program.

For 112 years marked by a passion for progress, Abdi İbrahim has actively embraced the green transformation by diligently integrating environmental considerations into its business models. Aligned with the ambitious 1.5°C target of the Paris Agreement, its greenhouse gas emission reduction targets boast the validation of the Science Based Targets Initiative (SBTi).

Materials and Methods

For more information you can also call 1-866-257-2597. What Are the Ingredients In Tadalafil Tablets? This Patient Information has been approved by the U.S. Food and Drug Administration *The brands listed are trademarks of their respective owners and are not trademarks of Solco Healthcare US, LLC. The makers of these brands are not affiliated with and do not endorse Solco Healthcare US, LLC or its products.

Publisher’s Note

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Container Label-5 mgRx onlyNDC 68788-8465Tadalafil tablets, USPTablets should not be split.Entire dose should be taken.Usual Dosage: See accompanying literature for dosage.Each tablet contains 5 mg of tadalafil, USP.Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°C to 86°F) [see USP Controlled Room Temperature].Warning: Keep out of reach of children.Dispense in a tight container.Print Patient Information at: by:Zhejiang Huahai Pharmaceutical Co., Ltd.Xunqiao, Linhai, Zhejiang 317024, ChinaDistributed by:Solco Healthcare US, LLCSomerset, NJ 08873, USARevised. Usual Dosage: See accompanying literature for dosage. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°C to 86°F) [see USP Controlled Room Temperature]. Warning: Keep out of reach of children. Product ACETYLSALICYLIC ACID /100 mg Enteric Coated TabletPlatelet aggregation inhibitors (COX inhibitors) Product OLANZAPINE /2.5 mg & 5 mg & 10 mg & 20 mg TabletAtypical Antipsychotics - Schizophrenia Product FLUTICASONE + SALMETEROL /50 mcg/100mcg Dry Powder InhalerAdrenergics (B2 agonists) in combination with corticosteroids - Asthma erectile dysfunction pills tadalafil & COPD Product LEVOTHYROXINE SODIUM /25mcg; 50mcg; 75mcg; 100mcg; 125mcg; 150mcg; 200mcg TabletThyroid Preparations - Hypothyroidism Product LEVETIRACETAM / 500 mg & 750 mg & 1000 mg TabletAntiepileptic Product ESCITALOPRAM / 5 mg; 10 mg; 20 mg Tablet; 10 mg/ml oral dropsSelective serotonin reuptake inhibitors - Antidepressants Product ENTECAVIR / 0,5 mg; 1 mg TabletNucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B Product TENOFOVIR DISOPROXIL / 245 mg TabletNucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B Product OTILONIUM + SIMETICONE / 40 mg + 80 mg TabletAnticholinergics & anti-floating agents (combi)- Functional gastrointestinal disorders Product LEVOCETIRIZINE + MONTELUKAST / 5 mg + 10 mg TabletAntihistaminics & Leukotriene receptor antagonists (combi)- Rhinitis & Asthma News Abdi İbrahim Receives 'Equal Opportunity Model' Certificate for Women's EmploymentAbdi İbrahim has been awarded the 'Equal Opportunity Model' (FEM) certificate, developed by KAGIDER with the technical support of the World Bank, to promote gender equality in business life and enhance women's productivity.

Authors and Affiliations

Deniz Daver, President of Human and Culture Group, expressed their happiness in receiving this certificate, stating, “This certificate, which acknowledges companies' sensitive approaches to gender equality and women's empowerment in employment, is an important indicator reflecting Abdi İbrahim's vision of inclusiveness. We see FEM certificate as a reward for our determined and continuous efforts in this field. Brochure HEALING THE LIVES, HEALING THE FUTURE THAT’S WHAT WE DO.Turkish pharmaceutical industry leader Abdi Ibrahim s journey began in 1912.In addition to its partnerships with more than 30 licensing firms across the globe, Abdi Ibrahim develops its own products with 250 brands and 500 products.Abdi Ibrahim has subsidiaries operating in 17 countries outside Turkey, exports to more than 70 countries from the European Union to Canada, North Africa to Asia and generates the highest employment rate in the Turkish pharmaceutical industry with 5500 qualified employees. News R&D Award to Abdi İbrahim in 5 CategoriesAbdi İbrahim, the uninterrupted leader of the Turkish pharmaceutical industry for 21 years, received awards in 5 categories at the Crystal Mortar Awards organized by the Chemists' Association.Acting for 111 years with the mission of improving life, Abdi İbrahim received awards in 5 categories at the Crystal Mortar Awards, given within the scope of the 11th International Pharmaceutical Chemistry Congress for its R&D studies and investments. On the opening day of the 11th International Pharmaceutical Chemistry Congress organized by the Chemists' Association in Antalya this year, the R&D activities of pharmaceutical companies were awarded in 7 categories. Aligned with this target, the Company is resolutely aiming to curtail its Scope 1 and Scope 2 greenhouse gas emissions by 60 percent, and its Scope 3 emissions by 45 percent by 2030, measured against the baseline year 2020. News Abdi İbrahim Foundation Launches "Brave Strokes" Swimming Program for Children with Down SyndromeEstablished in 2021 by Abdi İbrahim, the healing power of Türkiye, the Abdi İbrahim Foundation aims to impart swimming skills to children aged 5 to 8 with Down Syndrome through the social responsibility project, Brave Strokes. This initiative is realized in collaboration with the Down Syndrome Association of Türkiye.Abdi İbrahim, the undisputed leader of the Turkish pharmaceutical industry for 22 years, has initiated a new project under the Abdi İbrahim Foundation, as part of its social investment programs that aim to create value for the country and society by healing the lives it touches. News Abdi İbrahim Publishes 6th Sustainability ReportConducting its sustainability operations with the vision of “Healing the Future,” Abdi İbrahim has released its 6th Sustainability Report, covering the period of 2021-2022.

5.6 Alpha-blockers and Antihypertensives

Aligned with the ambitious 1.5°C target of the Paris Agreement, its greenhouse gas emission reduction targets boast the validation of the Science Based Targets Initiative (SBTi). Aligned with this target, the Company is resolutely aiming to curtail its Scope 1 and Scope 2 greenhouse gas emissions by 60 percent, and its Scope 3 emissions by 45 percent by 2030, measured against the baseline year 2020. News Abdi İbrahim Foundation Launches "Brave Strokes" Swimming Program for Children with Down SyndromeEstablished in 2021 by Abdi İbrahim, the healing power of Türkiye, the Abdi İbrahim Foundation aims to impart swimming skills to children aged 5 to 8 with Down Syndrome through the social responsibility project, Brave Strokes. This initiative is realized in collaboration with the Down Syndrome Association of Türkiye.Abdi İbrahim, the undisputed leader of the Turkish pharmaceutical industry for 22 years, has initiated a new project under the Abdi İbrahim Foundation, as part of its social investment programs that aim to create value for the country and society by healing the lives it touches. News Abdi İbrahim Publishes 6th Sustainability ReportConducting its sustainability operations with the vision of “Healing the Future,” Abdi İbrahim has released its 6th Sustainability Report, covering the period of 2021-2022.

News Abdi İbrahim and GSK Türkiye Make Major Investment for Domestic Production of Respiratory Medicine

The report includes Abdi İbrahim’s sustainability goals set for 2030, 2040, and 2050, within the framework of healing the future of the ecosystem, people and business, along with the projects carried out in line with these goals. Abdi İbrahim’s sustainability report offers a unique reading experience with digital artworks designed by artist Bager Akbay and his team, combining human imagination with artificial intelligence.Planning its sustainability activities with a comprehensive perspective encompassing environmental, social, and governance aspects, Abdi İbrahim published its 6th Sustainability Report, detailing its sustainability efforts between January 1, 2021 and December 31, 2022.

What should I do if I accidentally use too much tadalafil?

The report includes Abdi İbrahim’s sustainability goals set for 2030, 2040, and 2050, within the framework of healing the future of the ecosystem, people and business, along with the projects carried out in line with these goals.

• Tadalafil 5mg is primarily used to treat erectile dysfunction.
• It works by relaxing blood vessels in the penis.
• Typically taken once daily for ongoing management.

Abdi İbrahim’s sustainability report offers a unique reading experience with digital artworks designed by artist Bager Akbay and his team, combining human imagination with artificial intelligence.Planning its sustainability activities with a comprehensive perspective encompassing environmental, social, and governance aspects, Abdi İbrahim published its 6th Sustainability Report, detailing its sustainability efforts between January 1, 2021 and December 31, 2022.

• In rare cases, tadalafil can cause vision changes.
• Allergic reactions may include rash, swelling, or difficulty breathing.
• Seek medical advice if side effects are severe or persistent.